A Phase 1a/1b Study of FPT155 in Patients with Advanced Solid Tumors.

Phase 1

• Conditions: Advanced Solid Tumors; Cancer - Any cancer

• Registration Number: ACTRN12618001955202
• Lead Sponsor: Five Prime Therapeutics, Inc.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-12-04
• Study Completion: 2021-08-10
• Last Update Posted: 9 August 2022

Recruitment & Eligibility

• Status: Stopped early
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

1. 18 years of age or older
2. Solid tumors (except primary CNS tumors)
3. For patients in Phase 1a dose escalation and Phase 1a dose exploration only: Disease that is unresectable, locally advanced, or metastatic and has progressed following all standard treatments or is not appropriate for standard treatments
4. All patients must have at least one measurable lesion at baseline
5. In good functional status (daily activity, physical ability)
6. Blood lab values within protocol specified limits

Only Key inclusion criteria is listed.

Exclusion Criteria

1. No significant medical condition (e.g. cardiac, infectious)
2. Active, known, or suspected autoimmune disease.
3. Untreated or active central nervous system (CNS) metastases.

Only Key exclusion criteria is listed.

Study & Design

• Study Type: Interventional
• Study Design: Not specified